The Roche, Novartis and Kraft Group-backed cancer therapy developer raised $182m in an upsized IPO where it floated above its range.

Sompo, Fujitsu and Relx-backed Palantir went public yesterday and fetched a $20.6bn valuation – only marginally above the $20.3bn it was worth in 2015.

UT Southwestern-founded Taysha Gene Therapies surpassed its goal after underwriters bought additional shares.

The Washington State University neurological drug developer has gone public after issuing 12 million shares priced at $17 each.

Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.

The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.

OSU's kidney dialysis technology provider has added about $36m to close its initial public offering, its shares having more than doubled in price.

The kidney dialysis technology provider has added about $36m to close its initial public offering, it shares having more than doubled in price.

Dell's stake in the software release technology provider is sized at almost $490m following an initial public offering in which it floated well above its range.

Lilly Asia Ventures achieved an exit as the gastrointestinal and liver disease drug developer priced its initial public offering in the middle of its range.